COVID-19 has had an extreme negative impact on countries around the world. Businesses were closed, economies were damaged, employees were forced to work form home, and everyone had to get used to wearing a mask and other practices considered to be the "new normal.” One industry that was not spared the wrath of COVID-19 was clinical trials.
The effort to protect trial participants led many companies to adopt technologies they had not used in the past. One of those is virtual or decentralized trials. Decentralized trials allow patients to participate in clinical studies without having to leave their homes. These studies make use of remote monitoring, digital devices, eDiaries, home healthcare visits, and other emerging technologies.
In this collection of articles from Clinical Leader, learn how sponsor companies are adapting to the new normal in clinical trials and reducing risk while creating tomorrow’s new study paradigms.